A 2026 single-center study of 89 breast cancer patients found that those with sufficient vitamin D levels before starting ribociclib treatment had dramatically better outcomes: 100% remained cancer-free at 24 months versus only 23% of those with vitamin D deficiency. According to Gram Research analysis, patients with deficient vitamin D had a median progression-free survival of 14 months compared to those with sufficient levels who hadn’t yet reached median survival, suggesting vitamin D status may predict treatment response in this cancer type.
A new study of 89 breast cancer patients found that those with healthy vitamin D levels lived much longer without their cancer getting worse compared to those with vitamin D deficiency. Patients with sufficient vitamin D had not yet reached the point where half their cancer progressed, while those lacking vitamin D saw their cancer progress after just 14 months. Though the results are promising, researchers emphasize this was a small study at one hospital, so larger studies are needed to confirm whether checking vitamin D levels could help doctors predict how well this particular cancer treatment will work.
Key Statistics
A 2026 single-center analysis of 89 patients with metastatic breast cancer found that those with sufficient vitamin D levels (above 20 ng/mL) had 100% progression-free survival at 24 months compared to 23.1% in the vitamin D-deficient group.
In a 2026 study of 89 breast cancer patients receiving ribociclib therapy, those with vitamin D deficiency had a median progression-free survival of 14 months versus those with sufficient vitamin D who had not yet reached median survival, representing a statistically significant difference (p < 0.001).
A 2026 retrospective analysis of 89 patients found that baseline vitamin D deficiency was associated with a 32-fold increased risk of cancer progression in patients treated with ribociclib-based therapy, though researchers note this estimate has wide confidence intervals due to limited progression events in the sufficient group.
According to a 2026 single-center study of 89 metastatic breast cancer patients, the median baseline vitamin D level was 19 ng/mL, indicating that most patients began ribociclib treatment with vitamin D deficiency.
The Quick Take
- What they studied: Whether vitamin D levels before starting cancer treatment could predict how long patients would stay cancer-free while taking ribociclib, a common drug for metastatic breast cancer.
- Who participated: 89 patients with advanced breast cancer (HR+/HER2- metastatic breast cancer) treated at one hospital between 2018 and 2023. All patients received ribociclib plus hormone therapy.
- Key finding: Patients with sufficient vitamin D levels (above 20 ng/mL) had dramatically better outcomes: their cancer didn’t progress for much longer than those with deficiency. At 24 months, 100% of the sufficient group remained cancer-free versus only 23% of the deficient group.
- What it means for you: If you have this type of breast cancer and are considering ribociclib treatment, your vitamin D level before starting might matter for predicting treatment success. However, this is early research from one hospital, so talk with your doctor before making any decisions based on these findings.
The Research Details
Researchers looked back at medical records from 89 patients who received ribociclib treatment between 2018 and 2023 at a single cancer center. They measured each patient’s vitamin D level before treatment started and divided them into two groups: those with deficient levels (20 ng/mL or lower) and those with sufficient levels (above 20 ng/mL). They then tracked how long each patient’s cancer stayed under control, comparing the two groups using standard statistical methods.
The main goal was to see if vitamin D levels could predict progression-free survival—the time before the cancer started growing again. Researchers used survival curves and statistical tests to compare the two groups and determine if vitamin D was independently linked to outcomes, even when accounting for other patient factors.
This type of study is called a retrospective analysis, meaning researchers examined existing data rather than following patients forward in time. While this approach is faster and less expensive, it has limitations because researchers can’t control for all the factors that might affect outcomes.
Understanding factors that predict treatment success helps doctors identify which patients might benefit most from specific therapies and which patients might need closer monitoring or additional support. If vitamin D status truly matters, it could lead to a simple, inexpensive test that improves treatment planning.
This study has several important limitations to consider: it’s small (only 89 patients), it’s from a single hospital, and it’s retrospective (looking backward at existing data). The vitamin D-sufficient group had very few cancer progressions, which made the statistical estimates uncertain (very wide confidence intervals). The researchers themselves note these findings are ’exploratory and hypothesis-generating,’ meaning they’re a starting point for future research, not definitive proof.
What the Results Show
The median vitamin D level across all patients was 19 ng/mL, indicating many patients started treatment with deficiency. The overall median progression-free survival was 36 months. However, this number hides a dramatic difference between groups: patients with sufficient vitamin D had not yet reached the point where half their cancers progressed (meaning they did very well), while patients with deficient vitamin D had a median progression-free survival of only 14 months.
At the 24-month mark, the difference was striking: 100% of patients with sufficient vitamin D remained cancer-free, compared to only 23.1% in the deficient group. When researchers used statistical modeling to account for other patient factors, vitamin D deficiency remained strongly associated with worse outcomes, with a hazard ratio of 32.33 (meaning deficient patients had about 32 times higher risk of cancer progression).
Other patient characteristics like age, stage of disease, or previous treatments did not show statistically significant links to survival outcomes in this study. This suggests vitamin D status may be particularly important for predicting outcomes in this specific treatment scenario.
The study found that vitamin D deficiency was the dominant factor predicting treatment response in this patient group. No other measured clinical or pathological variables showed significant associations with progression-free survival, which is notable because it suggests vitamin D may play a unique role in how patients respond to ribociclib therapy.
Vitamin D has been studied in various cancers and appears to play roles in immune function and cell growth regulation. However, according to Gram Research analysis, this is one of the first studies specifically examining vitamin D’s link to outcomes in patients receiving CDK4/6 inhibitors like ribociclib. The dramatic difference observed here is larger than what’s typically seen in similar cancer studies, which is why researchers urge caution and call for larger confirmatory studies.
The study’s main limitations are its small size (89 patients), single-center location, and retrospective design. The vitamin D-sufficient group had very few cancer progressions, making the statistical estimates uncertain. The researchers couldn’t account for all possible factors affecting outcomes (like sun exposure, diet, or supplements patients might have taken). Additionally, the study was conducted at one institution, so results may not apply to all hospitals or patient populations.
The Bottom Line
Current evidence is insufficient to recommend checking vitamin D levels as a standard part of treatment planning for this cancer type. However, maintaining healthy vitamin D levels through sun exposure, diet, or supplements is generally recommended for overall health. If you have this type of breast cancer, discuss vitamin D status with your oncologist, but don’t make treatment decisions based solely on this single study. Larger, prospective studies are needed before vitamin D testing becomes standard practice.
This research is most relevant to patients with HR+/HER2- metastatic breast cancer considering ribociclib treatment, and to their oncologists. It may also interest researchers studying how nutrition affects cancer treatment response. However, patients with other cancer types or receiving different treatments should not assume these findings apply to them.
If vitamin D status truly matters, benefits would likely appear over months rather than weeks. The study showed differences emerging within the first 24 months of treatment. However, this is preliminary research, and individual responses vary greatly.
Frequently Asked Questions
Does vitamin D help breast cancer treatment work better?
A 2026 study of 89 patients suggests vitamin D status may predict how well ribociclib treatment works, with sufficient levels linked to much longer cancer-free survival. However, this is early research from one hospital, so larger studies are needed to confirm whether vitamin D actually improves treatment effectiveness.
What vitamin D level do I need for breast cancer treatment?
This study used 20 ng/mL as the cutoff between deficiency and sufficiency. Generally, doctors consider levels above 30 ng/mL optimal for overall health. Discuss your specific vitamin D target with your oncologist, as individual needs may vary.
Should I take vitamin D supplements if I have metastatic breast cancer?
Maintaining healthy vitamin D levels is generally recommended for overall health, but don’t start supplements based solely on this study. Talk with your oncologist before adding supplements, as they can interact with some cancer medications and need to be monitored.
How long does it take to see benefits from better vitamin D levels?
This study tracked patients over 24 months and found differences in that timeframe. However, this is preliminary research, and individual responses vary. Work with your doctor to establish realistic expectations for your specific situation.
Can I use this study to predict my cancer treatment outcome?
This study is too small and preliminary to predict individual outcomes. It’s hypothesis-generating research suggesting vitamin D may matter, but many other factors affect treatment response. Your oncologist can discuss your specific prognosis based on comprehensive evaluation.
Want to Apply This Research?
- If you have this cancer type and are on ribociclib, track your vitamin D levels every 3 months (with your doctor’s approval) and note them alongside your treatment response markers. Record the date, vitamin D level in ng/mL, and any changes in your cancer status or symptoms.
- Work with your healthcare team to maintain vitamin D levels above 20 ng/mL through a combination of safe sun exposure (10-30 minutes daily), vitamin D-rich foods (fatty fish, egg yolks, fortified milk), or supplements if recommended. Log these efforts in your health app to track consistency.
- Create a dashboard showing your vitamin D levels over time alongside your progression-free survival milestones. Set quarterly reminders to discuss vitamin D status with your oncologist. Track any correlation between vitamin D supplementation changes and treatment response, but remember this is personal tracking, not medical evidence.
This article summarizes research findings and should not be interpreted as medical advice. Vitamin D status and cancer treatment decisions must be discussed with your oncologist or healthcare provider. The study described is preliminary, retrospective, and from a single center; larger prospective studies are needed to confirm these findings. Do not start, stop, or change any cancer treatment or supplements based on this article alone. If you have metastatic breast cancer or are considering ribociclib therapy, consult with your medical team about whether vitamin D testing or supplementation is appropriate for your individual situation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.